Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Complex treatment of metachronous metastases of osteosarcoma with or without preoperative chemotherapy: comparative results Abstract ID : 1272 Submitted by : Anatolii Diedkov the 2016-02-14 09:39:02 Category : Others Typology : Poster Status : Validated Authorisation to disclose : Yes/Oui ------------------------------------Background: Lung metastasis development after treatment is a negative prognostic factor for the long-term results in patients with osteosarcoma. The main treatment method for such category of patients is surgical removal of all metastatic lesions. This approach helps to achieve a quite high survival rate. There is no doubt among the majority of professionals about obligation of chemotherapy, however the need of preoperative chemotherapy is still under consideration. Aim: To determine the preferable treatment regimen for patients with metastatic osteosarcoma. Methods: 46 patients (mean age – 22,4 years; 17 women and 29 men) with metachronous metastases of osteosarcoma were considered fully operable subsequent to the results of CT in National Cancer Institute (Kyiv, Ukraine) 2010 to 2015. Metastases were detected between 6 and 38 months after the treatment (median - 22.3 months). The patients were assigned to 2 treatment groups. First group (n = 23; 50.0 %) underwent preoperative and postoperative chemotherapy: ifosfamide 9 g/m2, etoposide 150 mg/m2 and carboplatin 450 mg/m2. Second group (n = 23; 50.0 %) received the same scheme of postoperative chemotherapy only. The survival rate was estimated using Kaplan-Meier analysis. Mean monitoring time was 20 months (6 to 100). Results: 16 patients (69,6%) underwent surgery, 7 patients (30,4%) received radiotherapy (15 Gray on each lung) due to disease progression in 1 group. 23 patients (100%) were operated in 2nd group. Event free survival rate was 28,4 % in preoperative and postoperative chemotherapy group, and 35,8 % in postoperative chemotherapy group, median survival was 14,2 and 18,3 months, respectively (without statistical significant difference). The chemotherapy toxicity was assessed according to Common Terminology Criteria for Adverse Events (CTCAE v.3.0). 26,5% of 1st group and 15,3% of the 2nd group was observed hematological toxicity grade 4 . Conclusion: Preoperative chemotherapy in metachronous metastases of osteosarcoma has shown no benefits on survival. We suggest that preferable treatment strategy for such patients is surgical treatment followed by chemotherapy. The acceptable toxicity allows to implement the planned treatment without deterioration of oncological outcomes. ------------------------------------Keywords : Authors : References : , , , Authors Anatolii Diedkov 1, Pavlo Kovalchuk 1, Sergiy Boichuk 1, Viktor Kostyuk 1, Tatiana Tarasova 1, 1. Orthopedic Oncology, National Cancer Institute, Kiev, UKRAINE Authors (raw format) Diedkov Anatolii - email : [email protected] Institution : National Cancer Institute Department : Orthopedic Oncology City : Kiev Country : UKRAINE Speaker : Yes Kovalchuk Pavlo - email : [email protected] Institution : National Cancer Institute Department : Orthopedic Oncology City : Kiev Country : UKRAINE Speaker : No Boichuk Sergiy - email : [email protected] Institution : National Cancer Institute Department : Orthopedic Oncology City : Kiev Country : UKRAINE Speaker : No Kostyuk Viktor - email : [email protected] Institution : National Cancer Institute Department : Orthopedic Oncology City : Kiev Country : UKRAINE Speaker : No Tarasova Tatiana - email : [email protected] Institution : National Cancer Institute Department : Orthopedic Oncology City : Kiev Country : UKRAINE Speaker : No